These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 14584965)

  • 1. Diquafosol: DE 089, diquafosol tetrasodium, INS 365, INS 365 Ophthalmic, INS 365 Respiratory, KPY 998.
    Drugs R D; 2003; 4(6):359-62. PubMed ID: 14584965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diquafosol tetrasodium. Inspire/Allergan/Santen.
    Fischbarg J
    Curr Opin Investig Drugs; 2003 Nov; 4(11):1377-83. PubMed ID: 14758778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diquafosol tetrasodium: a novel dry eye therapy.
    Nichols KK; Yerxa B; Kellerman DJ
    Expert Opin Investig Drugs; 2004 Jan; 13(1):47-54. PubMed ID: 14680452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.
    Keating GM
    Drugs; 2015 May; 75(8):911-22. PubMed ID: 25968930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diquafosol ophthalmic solution for dry eye treatment.
    Nakamura M; Imanaka T; Sakamoto A
    Adv Ther; 2012 Jul; 29(7):579-89. PubMed ID: 22843206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic evaluation of diquafosol tetrasodium for the treatment of Sjögren's syndrome.
    Bremond-Gignac D; Gicquel JJ; Chiambaretta F
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):905-13. PubMed ID: 24797483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye.
    Kaido M; Uchino M; Kojima T; Dogru M; Tsubota K
    J Ocul Pharmacol Ther; 2013; 29(6):595-603. PubMed ID: 23537148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjögren and Sjögren Syndrome Dry Eye Patients Unresponsive to Artificial Tear.
    Jeon HS; Hyon JY
    J Ocul Pharmacol Ther; 2016 Sep; 32(7):463-8. PubMed ID: 27294831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Diquafosol Ophthalmic Solution on Quality of Life in Dry Eye Assessed Using the Dry Eye-Related Quality-of-Life Score Questionnaire: Effectiveness in Patients While Reading and Using Visual Display Terminals.
    Utsunomiya T; Kawahara A; Hanada K; Yoshida A
    Cornea; 2017 Aug; 36(8):908-914. PubMed ID: 28542084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Topical Diquafosol Tetrasodium 3% on Dry Eye After Cataract Surgery.
    Baek J; Doh SH; Chung SK
    Curr Eye Res; 2016 Oct; 41(10):1281-1285. PubMed ID: 27049809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.
    Yamane M; Ogawa Y; Fukui M; Kamoi M; Saijo-Ban Y; Yaguchi S; Mukai S; Kawakita T; Simmura S; Tsubota K
    Optom Vis Sci; 2015 Apr; 92(4 Suppl 1):S25-32. PubMed ID: 25785527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.
    Yokoi N; Sonomura Y; Kato H; Komuro A; Kinoshita S
    Eye (Lond); 2015 Sep; 29(9):1204-12. PubMed ID: 26160526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition.
    Shigeyasu C; Yamada M; Akune Y; Tsubota K
    Jpn J Ophthalmol; 2015 Nov; 59(6):415-20. PubMed ID: 26310103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
    Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
    Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials.
    Nam K; Kim HJ; Yoo A
    Ophthalmic Res; 2019; 61(4):188-198. PubMed ID: 30654362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study.
    Zhang Q; Zhang H; Qin G; Wu Y; Song Y; Yang L; Yu S; He X; Moore JE; Moutari S; Palme C; Xu L; He W; Pazo EE
    J Ocul Pharmacol Ther; 2022 Mar; 38(2):133-140. PubMed ID: 35049373
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease.
    Mun Y; Kwon JW; Oh JY
    BMC Ophthalmol; 2018 Sep; 18(1):237. PubMed ID: 30185156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
    Hwang HS; Sung YM; Lee WS; Kim EC
    Cornea; 2014 Sep; 33(9):935-41. PubMed ID: 25055152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis.
    Toda I; Ide T; Fukumoto T; Ichihashi Y; Tsubota K
    Am J Ophthalmol; 2014 Mar; 157(3):616-22.e1. PubMed ID: 24528935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of diquafosol tetrasodium eye drop for persistent dry eye after laser in situ keratomileusis.
    Mori Y; Nejima R; Masuda A; Maruyama Y; Minami K; Miyata K; Amano S
    Cornea; 2014 Jul; 33(7):659-62. PubMed ID: 24858017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.